Navigation Links
Third Wave reports net loss of $18.9M for 2006

Madison, Wis. - Third Wave Technologies reported a smaller net loss of $18.9 million, or 45 cents per share in 2006, but the company experienced impressive growth in clinical molecular diagnostic revenue, according to a year-end financial report.

Third Wave, which develops molecular diagnostic products for use in clinical testing, said its $18.9 mil......

Full article >>> litigation will cause operating expenses to increase in 2007.

......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 02/22/07


Related biology technology :

1. Third Wave files countersuit vs. Digene in patent case
2. Stratagene to pay Third Wave $10.75M in patent case
3. Third Wave responds to Digene patent lawsuit
4. Third Wave seeks approval of Cystic Fibrosis test
5. Third Wave Technologies to raise $14.9M through private debt
6. Third Wave reports $5.2M third quarter loss
7. Third Wave reports another loss, stronger sales
8. Napier joins board of Third Wave Technologies
9. Third Waves revenues rebound
10. Third Wave reports clinical growth, continued loss
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):